Tiziana Life Sciences (LON:TILS) chairman and founder Gabriele Cerrone talks Proactive London's Andrew Scott through the company's update this morning which he describes as an important step in finding a solution to the current pandemic. It's filed a patent around the direct delivery method of Anti-Interlukin-6-Receptor Monoclonal Antibodies into the lungs using a handheld inhaler or nebuliser. Cerrone adds that the technology could also be applicable for use with other FDA approved mAbs and drugs.
Tiziana Life Sciences files patent application for its novel coronavirus treatment technology
Quick facts: Tiziana Life Sciences PLC
Price: 158.8 GBX
Market Cap: £274.57 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE